Crispr’s ability to cut genetic code like scissors has just started to turn into medicines. Now, gene editing pioneer ...

Clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) proteins are core components of fast-evolving therapeutic gene editing tools. Scientists have used CRISPR ...

(RTTNews) - Vertex Pharmaceuticals (VRTX), Thursday reported compelling long-term data for its CRISPR/Cas9 gene-edited therapy, PrCASGEVY, at the EHA Congress. In sickle cell disease trials, 95.6 ...

In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout year. In the spring, five patients with sickle cell disease began treatment with Casgevy, the first ...

Despite a lackluster launch, CASGEVY has significant potential in international markets, bolstering CRISPR's long-term value. Upcoming milestones and updates on CRISPR Therapeutics is currently ...

Personalized Gene Editing Saves Baby in Record Time In early 2025, researchers successfully treated a baby boy with a rare, life-threatening disease by giving him a version of the CRISPR gene editor ...

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Grant ...

CRISPR Therapeutics' stock decline is likely influenced by Editas Medicine's struggles, but CRISPR remains a distinct and stronger company with a promising long-term outlook. CRISPR's strategic ...

Labroots invites you to the 9th Annual Event in the CRISPR Virtual Event Series 2026 taking place on October 28th, 2026! This event will continue the conversation of the abilities of CRISPR-based ...

ZUG, Switzerland and BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the fourth quarter and full year ended December 31, 2025.